Companies / BOC Sciences / Mosunetuzumab
BOC Sciences

Mosunetuzumab | BOC Sciences

Mosunetuzumab is an anti-CD20 and anti-CD3 bispecific monoclonal antibody approved for the treatment of follicular lymphoma. It redirects T cells to engage and eliminate malignant B cells.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.
  • See More